June 21, 2023
Roche has made the difficult decision not to move forward with a new clinical trial for rugonersen and has initiated the search for an external partner to take over the development. The conclusion of this trial undoubtedly brings feelings of […]
Read more
June 19, 2023
AURORA, IL – Angelman Syndrome Foundation (ASF) proudly announces the launch of the Jacob Pritzker Fellowship Program in honor of late board president Fred Pritzker. The Jacob Pritzker Fellowship Program was created to address the ever-increasing need for more physicians who […]
Read more
January 6, 2023
The Angelman Syndrome Foundation is proud to announce their partnership with Genefund Future Angelman Syndrome (GFAS Ukraine) to launch a new clinic to better serve the community in Ukraine. “Bright people are always visible in dark times. In the most […]
Read more
September 21, 2022
The Angelman Syndrome Foundation is proud to announce their partnership with AngelmanUK to launch new clinics and expand existing clinics to better serve the community in the UK. “AngelmanUK is delighted to collaborate with the Angelman Syndrome Foundation (ASF) on […]
Read more
September 2, 2022
Angelman Syndrome Foundation (ASF) proudly announces the collaboration with OVID Therapeutics to advance understanding of AS via a contribution of crucial data collected in Ovid’s clinical trial for Angelman syndrome to the LADDER database. “The most important gift that industry […]
Read more
March 8, 2022
Angelman Syndrome Foundation (ASF) and Dup15q Alliance proudly announce their strategic partnership to launch the LADDER Learning Network, a new medical network specifically designed for individuals with Angelman syndrome (AS) and dup15q—two rare disorders affecting the q-arm of the […]
Read more
October 22, 2021
As part of a 2020 ASF funded study, Ben Philpot, PhD and Matt Judson, PhD at UNC School of Medicine have been developing a gene therapy strategy as a method to restore function of UBE3A. The early results were published […]
Read more
October 21, 2020
Mark Zylka, PhD and his team at UNC School of Medicine have been studying CRISPR-Cas9 as a method to unsilence the paternal copy of UBE3A. After ASF funded the project, the findings were so positive, the NIH provided additional funding of […]
Read more